Emerald Mutual Fund Advisers Trust Buys 20,350 Shares of CeriBell, Inc. $CBLL

Emerald Mutual Fund Advisers Trust raised its stake in shares of CeriBell, Inc. (NASDAQ:CBLL) by 26.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 98,185 shares of the company’s stock after purchasing an additional 20,350 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in CeriBell were worth $1,839,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in CBLL. KLP Kapitalforvaltning AS bought a new position in shares of CeriBell during the 1st quarter valued at about $36,000. New York State Common Retirement Fund bought a new position in shares of CeriBell during the 1st quarter valued at about $67,000. Quantbot Technologies LP bought a new position in shares of CeriBell in the 1st quarter valued at about $175,000. Rhumbline Advisers lifted its holdings in shares of CeriBell by 26.5% in the 1st quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock valued at $300,000 after acquiring an additional 3,276 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of CeriBell in the 1st quarter valued at about $311,000.

CeriBell Stock Performance

CeriBell stock opened at $12.03 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 13.31 and a quick ratio of 12.91. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $32.75. The firm has a market capitalization of $441.02 million and a P/E ratio of -4.02. The company’s 50-day moving average is $12.10 and its 200 day moving average is $14.72.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. The company had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. Research analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current year.

Insiders Place Their Bets

In related news, CTO Raymond Woo sold 11,112 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $12.54, for a total value of $139,344.48. Following the sale, the chief technology officer directly owned 167,704 shares of the company’s stock, valued at $2,103,008.16. This represents a 6.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CBLL has been the subject of a number of analyst reports. Raymond James Financial initiated coverage on shares of CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.